Synonyms: GM-611 | GM611
Compound class:
Synthetic organic
Comment: Mitemcinal is a non-peptide, orally active motilin receptor agonist that was developed by Chugai Pharmaceutical [6] as a prokinetic agent for the treatment of gastroparesis [5,7].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Clark MJ, Wright T, Bertrand PP, Bornstein JC, Jenkinson KM, Verlinden M, Furness JB. (1999)
Erythromycin derivatives ABT 229 and GM 611 act on motilin receptors in the rabbit duodenum. Clin Exp Pharmacol Physiol, 26 (3): 242-5. [PMID:10081621] |
2. Koga H, Sato T, Tsuzuki K, Onoda H, Kuboniwa H, Takanashi H. (1994)
Potent, acid-stable and orally active macrolide-type motilin receptor agonists, GM-611 and the derivatives. Bioorg Med Chem Lett, 4 (11): 1347-1352. |
3. McCallum RW, Cynshi O, Investigative Team. (2007)
Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther, 26 (8): 1121-30. [PMID:17894654] |
4. McCallum RW, Cynshi O, US INVESTIGATIVE TEAM. (2007)
Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther, 26 (1): 107-16. [PMID:17555427] |
5. Onoma M, Ozaki K, Yogo K, Monnai M, Muramatsu H, Kamei K, Kawabe Y, Hayashi S, Shiga T, Matsuo S et al.. (2008)
Mitemcinal (GM-611), an orally active motilin receptor agonist, improves delayed gastric emptying in a canine model of diabetic gastroparesis. Clin Exp Pharmacol Physiol, 35 (7): 788-96. [PMID:18346169] |
6. Peeters TL. (2001)
GM-611 (Chugai Pharmaceutical). Curr Opin Investig Drugs, 2 (4): 555-7. [PMID:11566017] |
7. Takanashi H, Cynshi O. (2009)
Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis. Regul Pept, 155 (1-3): 18-23. [PMID:19345243] |
8. Takanashi H, Yogo K, Ozaki K, Koga H, Itoh Z, Omura S. (2007)
In vitro pharmacological characterization of mitemcinal (GM-611), the first acid-resistant non-peptide motilin receptor agonist, in smooth muscle of rabbit small intestine. Pharmacology, 79 (3): 137-48. [PMID:17183187] |